ABSTRACT
A series of aryloxyazetidines, aryloxypyrrolidines and aryloxypiperidines were designed based on structural overlap with previously reported arylpyrazine Oxytocin antagonists. Similarly high levels of Oxytocin antagonism were achievable in these new series. Several aryloxyazetidines also showed high levels of selectivity, with one compound, 25, displaying promising in vivo pharmacokinetics and significantly improved aqueous solubility over related compounds containing a biaryl substituent.
Subject(s)
Antidiuretic Hormone Receptor Antagonists , Azetidines/chemistry , Oxytocin/analogs & derivatives , Triazoles/chemistry , Administration, Oral , Animals , Azetidines/chemical synthesis , Azetidines/pharmacokinetics , Dogs , Humans , Microsomes, Liver/metabolism , Oxytocin/chemistry , Oxytocin/pharmacokinetics , Rats , Receptors, Vasopressin/metabolism , Structure-Activity Relationship , Triazoles/chemical synthesis , Triazoles/pharmacokineticsABSTRACT
A novel series of Oxytocin antagonists are described. This series was identified through pharmacophoric overlap of in-house and literature antagonists. Subsequent optimization led to a series of potent, selective antagonists. Several analogues displayed oral bioavailability in vivo in the rat.
Subject(s)
Oxytocics/pharmacology , Oxytocin/antagonists & inhibitors , Triazoles/chemical synthesis , Triazoles/pharmacology , Administration, Oral , Animals , Combinatorial Chemistry Techniques , Molecular Structure , Oxytocics/chemical synthesis , Oxytocics/chemistry , Oxytocics/pharmacokinetics , Rats , Structure-Activity Relationship , Triazoles/chemistry , Triazoles/pharmacokineticsABSTRACT
Several potent aryl ether/triazole oxytocin antagonists are described. The lead compound in this series had significantly improved aqueous solubility over related systems containing a biaryl substituent.